Pharmaprojects R&D Pipeline News Feed
Update on Oncalis's novel anticancer among more news from BIO-Europe Spring
9th Mar 2007
Swiss pharmaceutical company Oncalis's update on its oncology-focused pipeline, and in particular its lead candidate ONC-101, was among the highlights from the final day of the BIO-Europe Spring meeting, held in Milan, Italy.
Announcing that it was looking for a partner for the drug, Oncalis's CEO, Dr Alcide Barberis, reported how ONC-101, a dual-specificity inhibitor of EphB4 and Raf, looks set to inhibit cell migration and proliferation, and thus offers huge potential for success in the clinic as a novel anticancer agent. ONC-101 could become the first EphB4 inhibitor to enter clinical trials.
A further exciting prospect in oncology is Sunesis Pharmaceuticals' Aurora kinase inhibitor, SNS-314, which was reported at the meeting to be expected to commence clinical trials in the 2nd quarter of 2007.
Amongst other presentations in the closing day of BIO-Europe Spring were those from specialist ophthalmic company OphthalmoPharma, which gave an excellent pipeline overview covering both out-licensing and co-promotion opportunities; and Indevus Pharmaceuticals which presented an informative R&D update, in the context of its imminent acquisition of Valera Pharmaceuticals.
